12 Most Profitable Growth Stocks to Buy According to Billionaires

Page 7 of 11

5. Eli Lilly and Company (NYSE:LLY)

TTM Net Income as of August 4: $11.11 billion

Number of Hedge Fund Holders: 119

Dollar Value of Billionaire Holdings: $13.74 billion

Number of Billionaire Investors: 23

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, Eli Lilly announced the topline results from its SURPASS-CVOT trial/NCT04255433, which is a phase III study that investigated the cardiovascular benefits of its dual-agonist drug Mounjaro (tirzepatide). The ~5-year trial involved 13,299 patients with type 2 diabetes and established atherosclerotic cardiovascular disease, comparing once-weekly Mounjaro against Trulicity (dulaglutide), which is another GLP-1 RA from Eli Lilly.

The study achieved its primary endpoint by demonstrating Mounjaro’s noninferiority to Trulicity in reducing the 3 major adverse cardiovascular events/MACE-3, which include cardiovascular death, heart attack, or stroke. Overall, Mounjaro reduced the MACE-3 by 8% compared to Trulicity. Analysts from William Blair and Citi expressed disappointment that the trial did not show superiority over Trulicity.

Mounjaro reduced MACE-3 by an estimated 28% and all-cause mortality by 39% when compared to a placebo. Additionally, Mounjaro led to greater improvements in A1C, weight, and cardiovascular biomarkers. A significant finding was a 16% lower rate of all-cause mortality compared to Trulicity, as well as greater kidney protection

Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the US, Europe, China, Japan, and internationally.

Page 7 of 11